ClinicalTrials.gov record
Recruiting Phase 2 Interventional

Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide With Metastasis-Directed Stereotactic Body Radiotherapy for the Treatment of Recurrent, Oligometastatic Prostate Adenocarcinoma

ClinicalTrials.gov ID: NCT07150715

Public ClinicalTrials.gov record NCT07150715. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 2:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide Combined With Metastasis-Directed Stereotactic Body Radiotherapy for Oligorecurrent Prostate Adenocarcinoma (ANDROMEDA)

Study identification

NCT ID
NCT07150715
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Enrollment
107 participants

Conditions and interventions

Interventions

  • Actinium Ac 225 Vipivotide Tetraxetan Drug
  • Biospecimen Collection Procedure
  • Gallium Ga 68 Gozetotide Other
  • Lutetium Lu 177 Vipivotide Tetraxetan Drug
  • PSMA PET-CT Scan Procedure
  • Stereotactic Body Radiation Therapy Radiation

Drug · Procedure · Other + 1 more

Eligibility (public fields only)

Age range
18 Years and older
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 11, 2025
Primary completion
Oct 30, 2030
Completion
Oct 30, 2031
Last update posted
Dec 16, 2025

2025 – 2031

United States locations

U.S. sites
1
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
UCLA / Jonsson Comprehensive Cancer Center Los Angeles California 90095 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07150715, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 16, 2025 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07150715 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →